anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject medicinal preparation which is useful for prophylaxis and therapy of diabetes complication with neuropathy, retinopathy, cataract and nephropathy because of its aldose reductase inhibitory action by culturing a bacterium belonging to the genus Streptomyces capable of producing a novel compound A-74863a. CONSTITUTION:A microorganism belonging to the genus Streptomyces capable of producing a novel compound, A-74863a, such as Streptomyces sp. SANK60593 (FERM-13P-4296) is inoculated into a culture medium and shaking-cultured for 7 days to prepare the seed culture. Then, the seed culture is placed in a jar frementer and cultured at 28 deg.C for 5 days, added with acetone, stirred at room temperature for 30 minutes and filtered by suction after added with Celite. The filtrate is concentrated under reduced pressure to remove acetone, adjusted its pH to 3, and extracted with ethyl acetate. The extract is concentrated under reduced pressure and the concentrate is purified by passing it through silica gel column to give a novel compound, A-74863a of the formula. The compound is used as an active ingredient to give the objective aldose reductase inhibitor preparation.
A dosage form of a shearable gel including at least one ingredient that requires taste masking. Taste masking is achieved by through the use of an oil/ water emulsion comprising over 14% by weight of the lipid-based carrier as compared to the water content of the dosage form. Up to 30% by weight of the lipid-based carrier may be included. The gel releases its load when sheared, the oil emulsion droplets providing a temporary coating on the tongue blunting the taste of the ingredient requiring masking. At least one agarose-based gelling agent is included at concentrations of 0.001g – 0.03g per gram of water in the dosage form. The lipid-based carrier may be chosen from olive oil, sunflower oil, coconut oil and medium chain triglyceride (MCT). The emulsifier may be chosen from lecthin, polyethylene glycol (PEG) or polysorbate 80. The ingredients requiring taste-masking are chosen from a protein, vitamin, mineral, plant or marine extract. The gel is provided in a sachet with a straw or opening for sucking or squeezing the gel out of the sachet.
PROBLEM TO BE SOLVED: To obtain a flexible capsule with no animal gelatin, and useful for coating balls, medicinal gelatin capsules or the like, by including vegetable starch modified so as to have properties similar to those of gelatin. SOLUTION: This capsule is such one as to be limited in closed inner chamber, contain no animal gelatin, have mechanical strength and flexibility each pref. at >=80% based on those of a reference film of gelatin and include vegetable starch modified so as to have gelatin-like properties. This capsule is desirable to contain the above-mentioned starch at about 20-80 wt.%, water at about 10-70 wt.% and a plasticizer (e.g. glycerol) at about 5-60 wt.%. It is desirable that the above-mentioned starch contains previously gelatinized oxidized wheat and another kind of starch, and also contains polyvinyl alcohol.
The proposed study was based upon a careful and thorough review of the scientific literature describing CNB effects on cognitive test performance and driving, as well as current state-of-knowledge on the sensitivity of biological assays for identifying recent CNB use. The study will carefully characterize the persistence of CNB's acute effects on cognitive test performance and driving over a several-hour time span. This will allow us to identify the point at which any effects of CNB intoxication driving-related cognitive tests, and driving performance cannot be distinguished from normal, i.e., the first step towards establishing standards for legal and social policy. The data obtained from simulated driving, cognitive tests, and biological assays of THC will be used in analyses aimed at identifying what tests or combination of tests predict both recent use and driving impairment risk.

This study will consist of 2 days (screening visit and dose visit). In a non-randomized, single blinded study, we will dose participants with placebo and high THC marijuana, about an hour apart, using paced inhalation through a vaporizer, an efficient means of delivering a standard THC dose. Participants will be told that the order they receive the doses will be random but they will always receive the placebo first, followed by the high dose. This will allow for standardization across all subjects and comparative values between placebo and drug. After inhaling the placebo dose, participants will be asked to complete one round of cognitive testing and a shortened version of the driving simulator (10 mins vs 30 mins). Approximately one hour post placebo dose, subjects will be administered high THC marijuana. Following this dosing, we will assess impairment through cognitive testing as well as a simulated driving test and neuropsychological tests. Samples of blood will also be collected at multiple time points throughout the study visits to be measured for THC concentration and its metabolites. This allows clarification between the relationship of impairment, as well as subjective and objective intoxication, and levels of THC and it's metabolites in the users system.
Objective: To evaluate the impact of self-crosslinked hyaluronic acid (SCH) gel on endometrium recovery after artificial abortion. Methods: A multicenter, prospective randomized controlled trial was conducted across 18 hospitals from December 2021 to February 2023, involving 382 women who underwent artificial abortion. Participants were randomly allocated to receive either treatment with SCH gel (SCH group) or no treatment (control group) in a 1∶1 ratio. The primary outcome was endometrium thickness in 14 to 18 days after the first postoperative menstruation. Secondary outcomes included changes in menstrual volume during the first postoperative menstruation, menstruation resumption within 6 postoperative weeks, time to menstruation resumption, duration of the first postoperative menstruation, and incidence of dysmenorrhea. Results: Baseline characteristics of participants were comparable between the two groups (all P>0.05), with 95.3% (182/191) in SCH group and 92.7% (177/191) in the control group completed the study. The postoperative endometrial thickness in SCH group was significantly greater than that in the control group [(9.78±3.15) vs (8.95±2.32) mm; P=0.005]. SCH group also had significantly fewer participants with reduced menstrual volume [23 cases (12.6%, 23/182) vs 31 cases (17.5%, 31/177); P=0.038]. Although SCH group experienced less dysmenorrhea during the first postoperative menstrual period, this difference was not statistically significant [28.5% (51/179) vs 37.1% (65/175); P=0.083]. Outcomes were similar between SCH group and the control group regarding the proportion of participants who resumed menstruation within 6 weeks postoperatively, time to menstruation resumption, and duration of the first postoperative menstruation (P=0.792, 0.485, and 0.254, respectively). No serious adverse events were observed during the study period, and no adverse events were attributed to SCH gel treatment. Conclusion: The application of SCH gel after artificial abortion is safe and might aid in the recovery of the endometrium.
A polypeptide and a nucleic acid encoding the polypeptide are described. The polypeptide includes a cytotoxic toxin, a targeting domain that selectively binds to a target cell that is a mucus-secreting cell and a translocating domain that translocates the cytotoxic toxin into the target cell. A nucleic acid encoding the polypeptide is also described. Also described is a pharmaceutical composition for topical administration to a patient suffering from mucus hypersecretion which includes the polypeptide and a formulation component selected from the group consisting of an excipient, an adjuvant and a propellant. Methods of treating hypersecretion of mucus, chronic obstructive pulmonary disease (COPD) or asthma are also described. These methods include administering to a patient in need thereof a therapeutically effective amount of the polypeptide.
Percutaneous nephrolithotomy (PCNL) is currently the gold standard for treatment of patients with large and complex renal calculi because it is less invasive than open surgery. The sources of acute pain after PCNL are visceral pain originating from kidneys and ureters, and somatic pain from the site incision. PCNL is usually done in 10th to 11th intercostal space or in the subcostal area. Complete blockade of unilateral spinal nerves from T10 to L2 can provide sufficient analgesia during PCNL. This can be achieved by several regional techniques such as thoracic paravertebral block, transversus abdominis plane (TAP) block, erector spinae plane block (ESPB).

ESPB is an interfascial block which can provide wide sensory blockade from T2-4 to L1-2 that was first described in 2016. ESPB can be performed by injecting the local anesthetic in the deep interfascial plane of the erector spinae muscle with nearly one dermatome for each 3.4 ml of the injected volume. This allows ESPB to provide both visceral and somatic analgesia. TAP block is a regional injection of a local anesthetic agent between the transversus abdominis and internal oblique muscle planes. TAP block affects the sensory nerves of the anterolateral abdominal wall (T6-L1). Various technical modifications in TAP block have been described including lateral, posterior, subcostal, and continuous catheter techniques. The posterior approach should be the preferred technique in clinical practice as it provides longer somatic and visceral analgesia that are not offered with the lateral approach.
Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology. Healthy control subjects will also be recruited for this study.
This is a prospective, multi-center, randomized control clinical trial, aimed to demonstrate if ERCC1 expression could predict the efficacy of platinum-based chemotherapy in patients with locally advanced or metastatic gastric cancer. A total of 180 patients are planned to be enrolled into the study. ERCC1 protein expression in paraffin-embedding tumor tissue is examined by immunohistochemistry (IHC). Patients with low ERCC1 expression (group L) will be treated with XP regimen. Patients with high ERCC1 expression will be randomized into group H-A or group H-B, and be treated with XP or DX regimen, respectively. The primary end point is progression free survival (PFS), and the secondary end points include the median overall survival, objective response rate (ORR),disease control rate(DCR), duration of response, safety(number and degree of adverse events), and the quality of life (QOL).
Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV SC-PEG was administered every 3 weeks (for a total of 10 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
The invention relates to a Chinese medicine preparation for treating chronic colitis. The preparation is prepared from the following raw materials in parts by weight: 10 parts of red sage root, 10 parts of rhizoma atractylodis macrocephalae, 10 parts of tuckahoe, 10 parts of shizandra berry, 10 parts of fried coptis root, 12 parts of evodia, 12 parts of myrobalam, 12 parts of costus root, 15 parts of endothelium corneum gigeriae galli, 15 parts of fried white paeony root, 15 parts of honey-fried licorice root, and 15 parts of cherokee rose. The preparation comprises all clinically accepted preparation types suitable for oral administration, preferably pills, powders, tablets, oral liquids and capsules prepared by the traditional preparation process or the modern preparation process. The selected drugs have the efficiency on invigorating qi and strengthening spleen, astringing lung and nourishing spleen, antidarrhea with astringent, and activating spleen to digest by functioning together. Proved by clinic application, the preparation has ideal curative effect on chronic colitis which can not be cured for a long term. The preparation has the advantages of quick action, no toxic or side effect, good tolerance property, and no recurrence after recovery.
This study investigated the effects of amygdalin (AMY, a cyanogenic glycoside widely distributed in the fruits and seeds of Rosaceae plants) on cardiac performance and ventricular remodeling in a rat model of myocardial infarction (MI). We also investigated whether the combination of AMY with exercise training (ExT) has a beneficial synergistic effect in treating MI rats. MI was induced by the ligation of the left anterior descending coronary artery in male SD rats. ExT or AMY treatment was started 1 week after MI and continued for 1 week (short-term) or 8 weeks (long-term). Cardiac function was evaluated by echocardiographic and hemodynamic parameters. Heart tissues were harvested and subjected to 2,3,5-triphenyl-tetrazolium chloride, Masson's trichrome, hematoxylin-eosin, and immunohistochemical staining. Gene expression was determined by quantitative polymerase chain reaction. Western blot gave a qualitative assessment of protein levels. AMY or ExT improved cardiac function and reduced infarct size in MI rats. AMY or ExT also suppressed myocardial fibrosis and attenuated inflammation in the infarct border zone of hearts from MI rats, as evidenced by inhibition of collagen deposition, inflammatory cell infiltration, and pro-inflammatory markers (interleukin 1β, interleukin 6, tumor necrosis factor-α, and cyclooxygenase 2). Notably, the effects of AMY combined with ExT were superior to those of AMY alone or ExT alone. Mechanistically, these beneficial functions were correlated with the inhibition of MI-induced activation of the transforming growth factor-β/Smad pathway. Collectively, AMY and ExT exert a synergistic effect on improving cardiac performance and ameliorating cardiac inflammation and fibrosis after MI, and the effects of long-term intervention were better than short-term intervention.
The invention relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating toothache and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following raw materials in parts by weight: 8-12 parts of fresh black nightshade, 1-3 parts of spreading hedyotis herb, 1-2 parts of kudzuvine root, 1-3 parts of reed rhizome and 0.5-1.5 parts of blackberrylily rhizome. The preparation method of the traditional Chinese medicine composition for treating toothache comprises the following steps: taking each raw material in parts by weight, and decocting with water to obtain a decoction. The traditional Chinese medicine composition for treating toothache, provided by the invention, does not have any toxic or side effects and drug dependence, and is simple in formula, low in cost, convenient to use and good in curative effect. Years of clinical applications prove that the effective rate is 100% and the cure rate is extremely high. The traditional Chinese medicine composition for treating toothache, provided by the invention, has the most prominent characteristics of being high in effective rate and cure rate, having no need of secondary medication, and being extremely low in relapse rate.
A health club exercise records system in which members to the health club are given a handheld device that is pre-programmed by the trainer or health club operator to record different exercise activities. The handheld device includes a built-in numeric keypad, a display monitor, and optical reader designed to communicate with a compatible ID tag located on or in the vicinity of the exercise activity data source. Loaded into the working memory of the handheld device is a pre-programmed exercise data collection program. The exercise data collection program displays one or more sub-routines to the member requesting the member to input information regarding the exercise. The sub-routines are specific to the exercise activity data source and present one or more prompts requiring the member to input information. The inputted information is stored in a temporary data file located on the handheld device or transmitted immediately to a permanent member data file on a local server located in the health club. The system may also include an uplink terminal for transmitting the data in the temporarily data file to a remote server connected to a network operations center. A fitness tools software program is loaded into the server for collecting and processing the data in the member's permanent data file which may be reviewed by the trainer and/or member.
Individuals with chronic kidney disease represent a growing population in adult and pediatric practices. This has resulted in a drive to optimize patient care and outcomes. Historically, healthcare outcomes focused on morbidity, mortality or complication rates, but failed to provide meaningful data on the value of medicine to patients and the quality of life gained or lost. Several studies have revealed that treatments aimed at minimizing morbidity and mortality in end-stage renal disease (ESRD) have very often been ineffective. Therefore, attention to HRQOL among ESRD patients is crucial.

The aim of this pilot study is creating and testing an electronic patient questionnaire that is suitable to measure health-related quality of life in Turkish dialysis patients. This questionnaire consists of the PROMIS Cognitive Function and Abilities Subset, the PROMIS-29, a new post-dialysis recovery time module, the MOS-Social Support Scale (MOS-SSS), Subscales of the KDQOL SF 1.3 (sexual function \& cognitive function), the General Self-Efficacy Scale and the Health Services Utilization And Productivity Loss Survey which are to be delivered together on a tablet computer.
Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
BACKGROUND: Peptide transporter 1 (PepT1) transports bacterial oligopeptide products and induces inflammation of the bowel. Nutritional peptides compete for the binding of intestinal bacterial products to PepT1. We investigated the mechanism of short-peptide-based enteral nutrition (SPEN) on the damage to the gut caused by the bacterial oligopeptide product muramyl dipeptide (MDP), which is transported by PepT1. The gut-lung axis is a shared mucosal immune system, and immune responses and disorders can affect the gut-respiratory relationship.
METHODS AND RESULTS: Sprague-Dawley rats were gavaged with solutions containing MDP, MDP + SPEN, MDP + intact-protein-based enteral nutrition (IPEN), glucose as a control, or glucose with GSK669 (a NOD2 antagonist). Inflammation, mitochondrial damage, autophagy, and apoptosis were explored to determine the role of the PepT1-nucleotide-binding oligomerization domain-containing protein 2 (NOD2)-beclin-1 signaling pathway in the small intestinal mucosa. MDP and proinflammatory factors of lung tissue were explored to determine that MDP can migrate to lung tissue and cause inflammation. Induction of proinflammatory cell accumulation and intestinal damage in MDP gavage rats was associated with increased NOD2 and Beclin-1 mRNA expression. IL-6 and TNF-α expression and apoptosis were increased, and mitochondrial damage was severe, as indicated by increased mtDNA in the MDP group compared with controls. MDP levels and expression of proinflammatory factors in lung tissue increased in the MDP group compared with the control group. SPEN, but not IPEN, eliminated these impacts.
CONCLUSIONS: Gavage of MDP to rats resulted in damage to the gut-lung axis. SPEN reverses the adverse effects of MDP. The PepT1-NOD2-beclin-1 pathway plays a role in small intestinal inflammation, mitochondrial damage, autophagy, and apoptosis.
Conduct transvaginal ultrasound imaging in accordance with ultrasound manufacturer recommendations.

ExEm Foam in the fallopian tube will appear as an echogenic line along the length of the tube on the image.

A fallopian tube is classified as patent if ExEm Foam is observed to pass from the tube and spill into the peritoneal cavity. The tube will appear as a thin, bright line. 

A fallopian tube is classified as occluded if ExEm Foam is not observed to pass from the tube and spill into the peritoneal cavity. As secondary findings, (1) there may be no bright line due to no flow into the fallopian tube, or (2) the tubal lumen may appear distended and contrast ﬂow might be observed only in the intramural or isthmic part of the tube.
PURPOSE: Provided are flavonoid derivatives which are useful for the prevention and treatment of osteoporosis. In particular, flavonoid derivatives and their pharmaceutically acceptable salts promote the cell growth of osteoblast but inhibit the cell growth of osteoclast. CONSTITUTION: The flavonoid derivative is a polyphenolic compound represented by the formula(1) or (2). It inhibits the cell growth of osteoclast but promotes the cell growth of osteoblast, thus has prophylaxis and therapeutic effects on osteoporosis. In the formula(1), R1, R2, R3, R4 and R5 are defined as in the description. A pharmaceutical composition used as a prophylaxis and therapeutic agent comprises the flavonoid derivative or its pharmaceutically acceptable salt as an active ingredient.
Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
FIELD: medicine, homeopathy. SUBSTANCE: agent has colocynthis, magnesium phosphoricum, arnica, cocculus and belladonna taken at the definite dilution. An agent improves elasticity of vessel walls, normalizes activity of vegetative nervous system and shows the stable therapeutic effect. An agent can be as a spasmolytic drug of the broad spectrum of effect. EFFECT: enhanced effectiveness of an agent. 1 cl, 2 ex
This is an open-label (both participant and investigator know the name of the medication given at a certain moment), single-arm, multicenter study in HCV treatment-naive and treatment-experienced patients infected with both chronic HCV-1 and HIV-1 to determine the efficacy and safety of telaprevir given with Peg-IFN-alfa-2a and RBV. The study will consist of 3 phases: a screening phase, an open-label treatment phase up to 48 weeks, and a follow-up period of 24 weeks. All patients will receive 12 weeks of treatment with telaprevir given with Peg-IFN-alfa-2a and RBV. At week 12 telaprevir dosing will end and patients will continue on Peg-IFN-alfa-2a and RBV. The total treatment duration in this study will be 24 or 48 weeks depending on the patient's prior HCV treatment status, liver disease status, and individual on-treatment virologic response in this study (equal response guided therapy). The maximum total duration of participation in the study for an individual participant will be approximately 76 weeks (screening included). Approximately 150 patients infected with both chronic HCV-1 and HIV-1 are planned to be enrolled.